SUMMARY We identified over 100 recipients of rabies vaccine (human diploid cell vaccine) and recruited them as plasma donors. Some were plasmapheresed at static centres, others by mobile teams. The operation of these teams is described in detail. No plasma was sent to the Fractionation Centre until the date of vaccination had been checked. Assay results showed that the majority of plasma collected between four and 20 weeks after the second dose of vaccine contained 6 or more IU/ml.
Rabies may return to Britain. In the past few years rabies has become endemic among the wild life of northern France with the constant risk that domestic animals will be bitten and the disease transmitted to man.
Until recently rabies vaccines were poorly immunogenic, and vaccination did not give a satisfactory degree of lasting immunity. ' We have demonstrated that a well-trained, mobile, blood-collecting team is quite capable of carrying out plasmapheresis in a district general hospital far from its base if careful arrangements are made in advance. The help of the two hospital blood banks has allowed us to carry out plasmapheresis without deploying the mobile blood processing laboratory whose main purpose is to prepare platelet concentrates and fresh frozen plasma from whole blood as soon as possible after donation.
The inventory system has worked well and has ensured that all plasma sent for specific immunoglobulin preparation has in fact been taken from well vaccinated donors within the five-month optimum periods.
We gave considerable thought to the timing of plasmapheresis. The assays confirmed initial fears that antibody responses would be less than ideal if plasma were collected before the third dose of vaccine had been given. However, we knew that only a limited number of people would be vaccinated and that there would be very few pre-exposure vaccinations in the following years unless rabies became a serious clinical problem. By that time it would be too late as the anti-rabies immunoglobulin would be required urgently for post-exposure cases. We also had some doubts about how many vaccinees would receive their third dose but these fears proved unfounded.
The assay results illustrate the prompt antibody response to two doses of cell culture vaccine and show sustained high levels of antibody for 20 weeks after the second dose in about two-thirds of donors. A lower proportion of plasma collected later had satisfactory antibody levels and should not be used for specific immunoglobulin preparation unless assays of neutralising activity are available.These require live rabies virus, and practical difficulties have prevented our obtaining assays on donations taken after the third dose of vaccine.
It is most important to emphasise that the antibody levels required for immunoglobulin preparation are much higher than those required for protection of the individual. Thus, we have every reason to believe that the donors have a good level of personal immunity even when their plasma contains less than 6 IU/ml of neutralising antibody.
